Geometrical Measurement of Central Tumor Location in cT1N0M0 NSCLC Predicts N1 but Not N2 Upstaging.


Journal

The Annals of thoracic surgery
ISSN: 1552-6259
Titre abrégé: Ann Thorac Surg
Pays: Netherlands
ID NLM: 15030100R

Informations de publication

Date de publication:
04 2021
Historique:
received: 12 03 2020
revised: 20 05 2020
accepted: 15 06 2020
pubmed: 28 8 2020
medline: 7 4 2021
entrez: 28 8 2020
Statut: ppublish

Résumé

In patients with non-small cell lung cancer (NSCLC) and normal mediastinum, the central tumor location predicts occult nodal disease (both N1 and N2). We evaluated a novel definition of central location based on a geometrical measurement of the tumor location within the lung that could predict N2, N1, or both. This retrospective study included patients with confirmed NSCLC, radiologically and metabolically staged T1 N0 M0, who underwent invasive mediastinal staging and/or lung resection. The central tumor location was measured considering 2 ratios. The inner margin ratio (IMR) and outer margin ratio (OMR) were both calculated as the distance from the inner margin of the lung to both margins of the tumor (inner [IMR], outer [OMR]) divided by the lung width. Optimal cutoffs for IMR and OMR were calculated. Tumors with values lower than the cutoffs were considered central. Prevalences of N1 and N2 upstaging were estimated and bivariate logistic regression analysis was performed to predict the odds of N1 and N2 upstaging using IMR and OMR cutoffs. A total of 209 patients were included. The prevalence of N1 and N2 upstaging was 11% and 5.3%, respectively. Cutoffs of 0.5 for IMR and 0.64 for OMR were estimated. Both ratios predicted N1 upstaging (adjusted odds ratio [95% confidence interval]: 4.2 [1.5-12]; P < .007; area under the curve, 0.65) but did not predict N2 upstaging. Central tumor location can be assessed by means of IMR and OMR and predicts N1 upstaging in patients with radiologically and metabolically T1 N0 M0 tumors. This is important for the selection of patients for therapies that require N0 tumors.

Sections du résumé

BACKGROUND
In patients with non-small cell lung cancer (NSCLC) and normal mediastinum, the central tumor location predicts occult nodal disease (both N1 and N2). We evaluated a novel definition of central location based on a geometrical measurement of the tumor location within the lung that could predict N2, N1, or both.
METHODS
This retrospective study included patients with confirmed NSCLC, radiologically and metabolically staged T1 N0 M0, who underwent invasive mediastinal staging and/or lung resection. The central tumor location was measured considering 2 ratios. The inner margin ratio (IMR) and outer margin ratio (OMR) were both calculated as the distance from the inner margin of the lung to both margins of the tumor (inner [IMR], outer [OMR]) divided by the lung width. Optimal cutoffs for IMR and OMR were calculated. Tumors with values lower than the cutoffs were considered central. Prevalences of N1 and N2 upstaging were estimated and bivariate logistic regression analysis was performed to predict the odds of N1 and N2 upstaging using IMR and OMR cutoffs.
RESULTS
A total of 209 patients were included. The prevalence of N1 and N2 upstaging was 11% and 5.3%, respectively. Cutoffs of 0.5 for IMR and 0.64 for OMR were estimated. Both ratios predicted N1 upstaging (adjusted odds ratio [95% confidence interval]: 4.2 [1.5-12]; P < .007; area under the curve, 0.65) but did not predict N2 upstaging.
CONCLUSIONS
Central tumor location can be assessed by means of IMR and OMR and predicts N1 upstaging in patients with radiologically and metabolically T1 N0 M0 tumors. This is important for the selection of patients for therapies that require N0 tumors.

Identifiants

pubmed: 32853568
pii: S0003-4975(20)31333-3
doi: 10.1016/j.athoracsur.2020.06.040
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1190-1197

Informations de copyright

Copyright © 2021 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Auteurs

José Sanz-Santos (J)

Department of Pulmonology, Hospital Universitari Mútua Terrassa, Terrassa, Spain; School of Medicine, University of Barcelona, Barcelona, Spain; Network of Centers for Biomedical Research in Respiratory Diseases (CIBERES) Lung Cancer Group, Terrassa, Spain. Electronic address: jsanzsantos@mutuaterrassa.cat.

Mireia Martínez-Palau (M)

Department of Pulmonology, Hospital Universitari Mútua Terrassa, Terrassa, Spain; School of Medicine, University of Barcelona, Barcelona, Spain.

Àngels Jaen (À)

Mútua Terrassa Foundation, Terrassa, Spain.

Ramón Rami-Porta (R)

Network of Centers for Biomedical Research in Respiratory Diseases (CIBERES) Lung Cancer Group, Terrassa, Spain; Department of Thoracic Surgery, Hospital Universitari Mútua Terrassa, Terrassa, Spain.

Bienvenido Barreiro (B)

Department of Pulmonology, Hospital Universitari Mútua Terrassa, Terrassa, Spain.

Sergi Call (S)

Department of Thoracic Surgery, Hospital Universitari Mútua Terrassa, Terrassa, Spain; Department of Morphological Sciences, Autonomous University of Barcelona, Bellaterra, Spain.

Carme Obiols (C)

Department of Thoracic Surgery, Hospital Universitari Mútua Terrassa, Terrassa, Spain.

José Manuel González (JM)

Diagnostic Technology Center, Hospital Universitari Mútua Terrassa, Terrassa, Spain.

José Ángel De Marcos (JÁ)

Department of Radiology, Hospital Universitari Mútua Terrassa, Terrassa, Spain.

Montserrat Ysamat (M)

Diagnostic Technology Center, Hospital Universitari Mútua Terrassa, Terrassa, Spain.

Lydia Canales (L)

Department of Radiology, Hospital Universitari Mútua Terrassa, Terrassa, Spain.

Mireia Serra (M)

Department of Thoracic Surgery, Hospital Universitari Mútua Terrassa, Terrassa, Spain.

Josep Belda (J)

Department of Thoracic Surgery, Hospital Universitari Mútua Terrassa, Terrassa, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH